A Phase 1 Trial of Intravenous Boronophenylalanine-Fructose Complex in Patients with Glioblastoma Multiforme
Seven patients with glioblastoma multiforme received 2-hour intravenous infusions of p-boronophenylalanine (BPA) prior to craniotomy. The BPA was solubilized for injection by complexation with fructose. Administered BPA doses were 100mg BPA/kg (n=1), 130 mg BPA/kg (n=5) and 170 mg BPA/kg (n=1). The boron concentration in blood was proportional to the administered dose. The boron concentrations in scalp were 1-2 times higher than the corresponding boron concentration in the blood. The boron concentrations in the tumor (range, 11–26µg 10B/g) were from 1–4 times the corresponding levels in the blood.
KeywordsBoron Concentration Biodistribution Study Boron Neutron Capture Therapy Brookhaven National Laboratory Prompt Gamma
Unable to display preview. Download preview PDF.
- 1.L.E. Farr, W.H. Sweet, J.S. Robertson, C.G. Foster, H.B. Locksley, D.L. Suntherland, M.L. Mendelsohn and E.E. Stickly, Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am. J. Roentgenol. 71: 279–291, 1954.Google Scholar
- 4.Y. Mishima, M. lchihashi, C. Honda, M. Shiono, T. Nakagawa, H. Obara, J. Shirakawa, J. Hiratsuka, K. Kanda, T. Kobayashi, T. Nozaki, O. Aigawa, T. Sato, H. Karashima, K. Yoshino and H. Fukuda, Advances in the control of cutaneous primary and metastatic melanoma by thermal neutron capture therapy. in: “Progress in Neutron Capture Therapy for Cancer,” B. Allen, D. Moore and B. Harrington, ed., Plenum Press, New York, 1992, pp 577–583.CrossRefGoogle Scholar
- 5.H. Fukuda, J. Hiratsuka, C. Honda, T. Kobayashi, K. Yoshino, H. Karashima. J. Takahashi, Y. Abe, K. Kanda, M. Ichihashi and Y. Mishima, Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat. Res. 138: 435–442, 1994.PubMedCrossRefGoogle Scholar
- 6.J.A. Coderre, D.D. Joel, P.L. Micca, M.M. Nawrocky and D.N. Slatkin, Control of intracerebral gliosarcoma in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat. Res. 129: 290296, 1992.Google Scholar
- 7.K. Yoshino, A. Suzuki, Y. Mori, H. Kanihana, C. Honda, Y. Mishima, T. Kobayashi and K. Kanda, Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlentherapie und Oncologie 165: 127–129, 1989.Google Scholar
- 10.Y. Mishima, M. Ichihashi and T. Nakanishi, Cure of malignant melanoma by single thermal neutron capture treatment using melanoma seeking compounds: l OB/melanogenesis interaction to in vitro/in vivo radiobiological analysis to preclinical studies. in: “Proceedings of the First International Symposium on Neutron Capture Therapy,” R. Fairchild and G. Brownell, ed., Brookhaven National Laboratory, Upton, 1983, pp 355–364.Google Scholar
- 12.J. Coderre, M. Makar, P. Micca, M. Nawrocky, H. Liu, D. Joel, D. Slatkin and H. Amols, Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 27: 1121–1129, 1993.PubMedCrossRefGoogle Scholar
- 14.J. Coderre, A phase 1 biodistribution study of p-boronophenylalanine. in: “Boron Neutron Capture Therapy: Towards Clinical Trials of Glioma with BNCT,” R. Moss and D. Gabel, ed.,. Plenum Press, New York, 1992, pp 111–121.Google Scholar